Related Experiment Video
Updated: Dec 24, 2025

Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection
Published on: February 16, 2020
Silver Nanoparticles for the Therapy of Tuberculosis
Alexandru-Flaviu Tăbăran1,2, Cristian Tudor Matea2, Teodora Mocan2,3
1Department of Pathology, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania.
Silver nanoparticles offer a novel approach to combat multidrug-resistant tuberculosis (TB). Further research is needed to address challenges like delivery and toxicity for effective TB therapy.
Area of Science:
- Nanomedicine
- Materials Science
- Infectious Diseases
Background:
- Multidrug-resistant Mycobacteria strains drive the global tuberculosis (TB) crisis.
- Limited new antibiotic development necessitates alternative therapeutic strategies.
- Nanotechnology presents novel solutions for enhancing TB treatment.
Purpose of the Study:
- To explore the potential of silver nanoparticles (AgNPs) as an alternative therapeutic for TB.
- To review the advantages and limitations of AgNPs in treating mycobacterial diseases.
- To provide an overview of mycobacterial disease pathology.
Main Methods:
- Literature review on silver nanoparticles in TB treatment.
- Analysis of AgNPs' efficacy against Mycobacteria.
- Evaluation of challenges in AgNP-based TB therapy.
Main Results:
- Silver nanoparticles show promise in overcoming drug resistance in TB treatment.
- AgNPs offer a potential new paradigm in antitubercular therapy.
- Key challenges include poor delivery, variable efficacy, and residual toxicity.
Conclusions:
- Silver nanoparticles (AgNPs) are promising adjuncts for treating mycobacterial diseases.
- Overcoming therapeutic hurdles is crucial for the clinical viability of AgNPs.
- Further research is essential to optimize AgNPs for effective TB medication.
More Related Videos
11:19Synthesis of Multi-walled Carbon Nanotubes Modified with Silver Nanoparticles and Evaluation of Their Antibacterial Activities and Cytotoxic Properties
Published on: May 10, 2018
11:52Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro
Published on: April 21, 2023
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...